S-1: Synergy CHC Files S-1 for $4.4M Common Stock Offering

Synergy CHC Corp. filed an S-1 registration statement to offer up to 1.28 million shares of common stock at $3.92 per share, aiming to raise approximately $4.4 million for working capital and general corporate purposes.

Summary

• Synergy CHC Corp. is offering up to 1,275,510 shares of its common stock, par value $0.00001 per share, at an assumed public offering price of $3.92 per share.
• The company expects to receive net proceeds of approximately $4.4 million from the offering, or $5.1 million if the underwriters exercise their over-allotment option in full.
• Proceeds are intended for working capital and general corporate purposes, with a focus on accelerating growth for FOCUSfactor supplements and FOCUSfactor energy Ready-to-Drink (RTD) products.
• Synergy CHC is a provider of consumer health care, beauty, and lifestyle products, with key brands FOCUSfactor (brain health supplement) and Flat Tummy (lifestyle and wellness nutritional products).
• For the year ended December 31, 2024, net revenue was $34.8 million, a 19% decrease from $42.8 million in 2023.
• For the six months ended June 30, 2025, net revenue was $16.3 million, a 6% decrease from $17.4 million in the same period of 2024.
• FOCUSfactor represented 88% of net revenue in 2024 and 86% for the six months ended June 30, 2025.
• The company's capital structure has historically been highly levered, with a focus on debt repayment, which limited business growth.
• The company operates an asset-light business model, partnering with third-party manufacturers.
• The offering will result in an immediate dilution of $4.68 per share to new investors, with the as-adjusted net tangible book value per share estimated at $(0.76).

Sentiment

Score: 6

Explanation: The filing outlines a capital raise to fund growth initiatives and improve liquidity, which is positive. However, it also highlights recent revenue declines and historical capital constraints, indicating challenges. The dilution for new investors is a negative factor, but the strategic direction and market opportunities present potential for future improvement.

Positives

• FOCUSfactor, a flagship brand, is clinically-tested and has expanded from 3 SKUs at acquisition to over 34 SKUs, demonstrating product line growth.
• Flat Tummy brand has expanded from 1 SKU to 13 SKUs and has a mobile app with approximately 1.97 million unique downloads as of June 30, 2025.
• The company has established distribution relationships with premier retailers including Costco, Amazon.com, Walmart, Walgreens, CVS, and Target.com.
• Successful pilot programs for FOCUSfactor RTD products were conducted in Texas (March-August 2023, sales $550-$2,382 per club/week) and Canada (April-July 2024, sales C$378-C$2,206 per club/week).
• The asset-light business model allows for quick and profitable scaling to meet demand, with diversified manufacturing partners.
• Working capital improved significantly from a deficit of $1.1 million at December 31, 2024, to a surplus of $12.4 million at June 30, 2025.
• Net income for the six months ended June 30, 2025, increased by 90% to $2.3 million compared to $1.2 million in the prior fiscal year period.
• EBITDA for the six months ended June 30, 2025, increased by 67% to $5.8 million compared to $3.5 million in the prior fiscal year period.

Negatives

• Net revenue decreased by 19% to $34.8 million for the year ended December 31, 2024, compared to $42.8 million in 2023, primarily due to rebranding and packaging upgrades for FOCUSfactor.
• Net revenue for the six months ended June 30, 2025, decreased by 6% to $16.3 million compared to $17.4 million in the same period of 2024.
• FOCUSfactor net revenue decreased 5% for the six months ended June 30, 2025, and 17% for the year ended December 31, 2024.
• The company's capital structure has been highly levered since 2015, with a historical focus on debt repayment limiting resources for business growth.
• The offering will result in immediate and substantial dilution of $4.68 per share to new investors.
• The company had a working capital deficit of $1.1 million at December 31, 2024.

Risks

• Operating in a highly competitive industry with competitors possessing significantly greater financial, technical, and marketing resources.
• Failure to appropriately respond to changing consumer preferences and demand for new products or product enhancements.
• Sales growth is dependent on maintaining relationships with a small number of large existing customers; loss of any could materially affect business.
• Reliance on outside suppliers and manufacturers; failure to supply products in sufficient quantities and timely fashion could harm the business.
• Adverse or negative publicity could cause the business to suffer.
• Inability to successfully execute on or realize expected benefits from strategic initiatives, which may also pose significant costs and risks.
• Potential for third parties to assert intellectual property infringement claims.
• Expansion into additional international markets exposes the company to significant operational risks.
• Potential for product recalls, withdrawals, or seizures, which could materially and adversely affect business.
• Compliance with numerous laws and regulations applicable to nutritional supplements, which may increase costs or limit sales.
• Risk of product liability claims and litigation.
• The trading price of common stock may fluctuate significantly due to various factors, including operating results, analyst recommendations, and general market conditions.
• A thin trading market or float for the stock could lead to higher volatility.
• Management will have broad discretion in using the proceeds from the offering, and their application may not improve results or enhance stock value.
• Sales of substantial amounts of common stock in the public market by existing stockholders could adversely affect the market price.

Future Outlook

The company intends to use the net proceeds from the offering to accelerate the growth of both its FOCUSfactor supplements and FOCUSfactor energy RTD products. Strategic plans include broadening media advertising, acquiring complementary brands, partnering with additional leading retailers to expand distribution (targeting 3-5 new SKUs across 3 potential retailers for ~50,000 new points of distribution), and diversifying geographic presence by entering Taiwan and Mexico in the second half of 2025, and Australia and Asia in the first quarter of 2026. New product development includes a FOCUSfactor supplement for Taiwan, RTDs for the UK, and focus and energy coffee for the United States in 2025, along with new Flat Tummy protein shakes, GLP-1 support products, and pre-workout powders in Q1 2025.

Management Comments

• Management's philosophy is to acquire promising brands that fit within health, beauty, and lifestyle offerings, and apply marketing and distribution strategies to develop brands to their full potential.
• Management believes they are adept at identifying promising opportunities that build out and complement the core brand portfolio.

Industry Context

The company operates within the growing nutritional supplement market, driven by increased consumer focus on health, beauty, and wellness, an aging population, increased obesity, pandemic concerns, and a desire for natural solutions. The brain health segment is projected to grow at 8% annually in the U.S. and 13% globally. The beverage market is large ($176 billion in 2022) and growing (8.6% CAGR 2022-2030), with an expanding range of functional benefits. The energy RTD category (U.S. sales of $19.2 billion in 2023, 6.3% CAGR 2018-2023) is evolving towards dual-benefit products, which Synergy CHC aims to capitalize on with its FOCUSfactor RTD. The U.S. nutritional supplements retail industry is highly fragmented with few barriers to entry, leading to intense competition from various manufacturers and retailers.

Comparison to Industry Standards

• The brain health segment is slated to grow at 8% per year in the United States and 13% per year globally, according to Grand View Research, indicating a favorable market trend for FOCUSfactor.
• The broader beverage market is projected to grow at an 8.6% CAGR from 2022 through 2030, and the energy RTD category specifically at a 6.3% CAGR from 2018 to 2023, suggesting strong industry tailwinds for FOCUSfactor's new RTD products.
• FOCUSfactor's formula does not rely as heavily on caffeine as competitors like Celsius, Bang, Reign, and C4, offering a differentiated product in the energy RTD market.
• The company acquired the FOCUSfactor brand in January 2015 for approximately 3x trailing EBITDA, which management considers an attractive valuation.

Corporate Governance

Related Party Transactions

• On March 8, 2022, the company entered into Securities Purchase Agreements for Senior Subordinated Debentures totaling $6,000,000 with Sanders Morris Harris, LLC and certain clients (Noteholders).
• Due to non-repayment of Principal Amount plus Loan Renegotiation Fee by December 31, 2024, the company issued 441,178 shares of common stock to the Noteholders.
• On May 29, 2025, the company satisfied $12,713,858 of debt owed to Knight Therapeutics International S.A. through a $10,000,000 cash repayment, an early payment discount of $1,213,858, and a conversion of $1,500,000 into equity, issuing a pre-funded common stock purchase warrant to Knight.

Stakeholder Impact

• Shareholders: Will experience immediate and substantial dilution from the offering, but the capital raise aims to fund growth initiatives that could enhance long-term value.
• Employees: Potential for increased stability and growth opportunities as the company expands and invests in its brands.
• Customers: May benefit from expanded product lines, new formulations, and broader distribution of FOCUSfactor and Flat Tummy products.
• Suppliers/Manufacturers: Continued and potentially increased demand for third-party manufacturing services due to the company's asset-light model and growth plans.
• Creditors: The capital raise and improved working capital position could enhance the company's financial stability and ability to meet its obligations.

Next Steps

• Complete the common stock offering to raise capital.
• Utilize net proceeds for working capital and general corporate purposes, specifically to accelerate growth of FOCUSfactor supplements and RTD products.
• Broaden media advertising strategy, including national television campaigns and online marketing.
• Evaluate and pursue acquisition opportunities that complement the existing brand portfolio.
• Partner with additional leading retailers to expand distribution footprint, aiming for 3-5 new SKUs across 3 potential retailers.
• Diversify geographic presence by entering Taiwan and Mexico in the second half of 2025, and Australia and Asia in the first quarter of 2026.
• Introduce new products: FOCUSfactor supplement for Taiwan, RTDs for the UK, and focus and energy coffee for the United States in 2025.
• Introduce new Flat Tummy protein shakes, GLP-1 support products, and pre-workout powders in Q1 2025.
• Continue to develop and expand current brands by reaching broader customer segments and leveraging existing retail networks.

Key Dates

Keywords

Synergy CHC Corp, SNYR, S-1, Common Stock Offering, Nasdaq Capital Market, Nutritional Supplements, Consumer Health, FOCUSfactor, Flat Tummy, Equity Raise, Public Offering, Brain Health, Wellness Products